ARGUS downgrades Genentech Inc. (NYSE: DNA) from Hold to Sell, and recommend that shareholders accept Roche's $95 per share offer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE